Naloxone Spray Global Market Report 2021: COVID-19 Implications And Growth – Yahoo Finance

Major players in the naloxone spray market are Emergent BioSolutions, Pfizer, Teva Pharmaceutical Industries Ltd. , Opiant Pharmaceuticals, Hikma Pharmaceuticals, Nasus Pharma, Amphastar Pharmaceuticals, Indivior PLC, Samarth Pharma Pvt.
New York, Oct. 25, 2021 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report "Naloxone Spray Global Market Report 2021: COVID-19 Implications And Growth" – https://www.reportlinker.com/p06177520/?utm_source=GNW
Ltd., Troikaa Pharmaceuticals Ltd., and Neon Laboratories Limited.

The global naloxone spray market is expected to grow from $285.09 million in 2020 to $351.39 million in 2021 at a compound annual growth rate (CAGR) of 23.3%. The change in growth trend is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2020. The market is expected to reach $785.35 million in 2025 at a CAGR of 22.3%.

The naloxone spray market consists of sales of naloxone spray by entities (organizations, sole traders, and partnerships) which is prefilled with naloxone a needle-free device that is sprayed into one nostril, and requires no assembly.It is used for treating an opioid emergency with symptoms such as problems with breathing and severe sleepiness or inability to respond.

Naloxone is a non-scheduled prescription drug, belongs to the class of medications called opiate antagonists, and is used to reverse or prevent the effects of opioid narcotic overdose for drugs such as codeine, fentanyl, morphine, and oxycodone. Naloxone comes as a solution (liquid) to spray into the nose and each naloxone nasal spray contains a single dose of naloxone and should be used only once.

The main types of dosages involved in the naloxone spray include 2 mg/actuation and 4 mg actuation. 2 mg/actuation sprays naloxone is equivalent to 1.8 mg naloxone and is used for emergency medication of known or suspected opioid overdose, as demonstrated by respiratory and/or central nervous system depression. The 2mg dose is licensed for use in opioid-dependent individuals who are at risk of severe opioid withdrawal and who live in an environment with a low risk of accidental or purposeful opioid exposure by household contacts. Naloxone sprays are available in various distribution channels such as hospitals, clinics, retail pharmacies, online pharmacies, others.

North America was the largest region in the naloxone spray market in 2020. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The increase in product approvals is shaping the naloxone spray market.Major companies manufacturing naloxone sprays are focused on new product approvals to broaden their product portfolios and expand their naloxone spray business.

For instance, in April 2021, the US Food and Drug Administration (FDA) approved Hikma Pharmaceuticals KLOXXADOTM (naloxone hydrochloride) nasal spray 8mg, for the immediate treatment of recognized or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, in adult and pediatric patients. KLOXXADOTM provides an important new treatment to address the opioid epidemic and contains twice as much naloxone per spray as Narcan Nasal Spray 4mg in a ready-to-use nasal spray to reverse the effects of opioid overdose.

In August 2019, Hikma Pharmaceuticals PLC, a UK-based pharmaceutical company acquired Insys Therapeutics Inc’s naloxone, epinephrine nasal sprays for an undisclosed amount.The acquisition enhances Hikma Pharmaceuticals PLC’s nasal spray capabilities, resulting in a comprehensive platform that can be used for both internal and external programs.

Insys Therapeutics Inc is a US-based company that manufactures naloxone, epinephrine nasal sprays.

The increasing prevalence of opioid overdoses is contributing to the growth of the naloxone spray market.Opioids include medicines such as morphine, fentanyl, and tramadol and are used for the treatment of pain.

However, due to their pharmacological effects, their non-medical use, prolonged use, misuse, and use without medical supervision can lead to opioid dependence and can cause breathing difficulties, or even lead to death or other health problems. For instance, in 2019, opioids were involved in 49,860 overdose deaths (70.6% of all drug overdose deaths). According to WHO, as of 2020, more than 70% of deaths are related to opioids, and out of these 30% of deaths are caused by overdose. As a part of emergency medical treatment, naloxone nasal spray is used to reverse the life-threatening effects of opiate or opioids overdose. Therefore, the increasing prevalence of opioid overdoses drives the growth of the naloxone spray market.

The countries covered in the naloxone spray market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Read the full report: https://www.reportlinker.com/p06177520/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.

__________________________

Yahoo Finance’s Jared Blikre breaks down the latest Apple earnings report.
Ever since Nvidia (NASDAQ: NVDA) released strong earnings results for the third quarter of fiscal 2022 on Nov. 17, 2021, the stock has been going downhill, due to a variety of factors out of the company's control. Shares of the graphics card specialist are down 30% since its Q3 report as the strong probability of interest rate hikes by the Federal Reserve and the crash in cryptocurrencies has weighed on investor sentiment. After all, interest rate hikes are bad news for richly valued companies such as Nvidia as rising U.S. Treasury yields mean that investors can get more returns by shifting their money to safer assets.
Chevron stock was falling in premarket trading on Friday after the oil giant missed earnings expectations. Shares were down 3% in premarket trading. “It’s primarily due to some noncash charges,” Chevron Chief Financial Officer Pierre Breber said in an interview with Barron’s. Breber pointed to items like depreciation and timing effects of inventory changes that “are hard for analysts to forecast.”
One top Wall Street auto analyst thinks this Tesla rival has a massively undervalued stock price. Here's why.
Jim Cramer has never been shy to use buzzers and bells to make the occasionally esoteric world of finance more interesting.
AMD's relatively cheap valuation and its ability to keep growing at a rapid pace make the stock worth buying.
Despite positive material updates, the biotech's shares couldn't escape the market-wide downturn among growth stocks this week.
The company's recovery from the pandemic is prolonged, with losses on the bottom line piling up.
Certainly you’ve been watching the stock market over the past few days. The recent stock market volatility, following years of up markets, is nevertheless the most widely forecast financial reversal in recent history. For them I offer a fundamental insight, one which can escape even seasoned investors.
Even the best stock pickers will make plenty of bad investments. And there's no doubt that Palantir Technologies Inc…
Investors may soon be able to preserve their retirement war chest for longer. The Securing a Strong Retirement Act, a bill originally pushed in 2021 but which may finally pass this year, would push the starting point for required minimum … Continue reading → The post RMDs May Soon Start Even Later for Retirement Plan Savers appeared first on SmartAsset Blog.
Over the next two decades, artificial intelligence (AI) will contribute $30 trillion to the global equity market cap, according to Ark Invest. It makes content and product recommendations more relevant. For instance, fintech companies like Upstart Holdings (NASDAQ: UPST) and Riskified (NYSE: RSKD) are using AI to minimize risk for banks and e-commerce merchants, helping them operate more efficiently and more profitably.
It's not something investors like to think about, but stock market crashes and corrections are a normal part of the investing cycle and the price long-term investors pay for admission to one of the world's greatest wealth creators. The tech-heavy Nasdaq Composite has entered correction territory, while the benchmark S&P 500 is contending with its worst slide in more than a year. While stock market corrections can be unnerving, they're also, historically, the perfect time to put money to work in the market — especially if your average holding period is measured in years.
In what follows, we'll look at two stocks that are changing hands for well under $100 per share and that look attractive at current levels: Pfizer (NYSE: PFE) and Teladoc Health (NYSE: TDOC). Pfizer's coronavirus lineup alone will likely generate more sales than most pharmaceutical companies this year. Meanwhile, Pfizer's newly approved coronavirus medicine, Paxlovid, could generate upward of $10 billion.
In this article, we discuss oil price predictions and the 10 best energy stocks to buy according to hedge funds. If you want to skip our detailed analysis of these stocks, go directly to 5 Best Energy Stocks to Buy for 2022. The energy industry had a record 2021 with oil stocks climbing to the […]
Stocks traded mixed Friday morning as investors took in earnings results from some major tech companies and another hot print on inflation at the end of another volatile week.
Yahoo Finance's Jared Blikre reports Visa's quarterly earnings and how the stock is performing.
Shares of Affirm Holdings Inc. have cratered 69% from their closing high set in November, and one analyst says that steep drop is "overdone."
The U.S. stock market hasn't had the best start to 2022. Pipeline giant Kinder Morgan (NYSE: KMI) and integrated solar solution provider SolarEdge Technologies (NASDAQ: SEDG) are two completely different businesses that are both worth buying now. Kinder Morgan is the U.S. leader in natural gas pipeline infrastructure.
For his second "Executive Decision" segment of Mad Money Thursday evening, Jim Cramer spoke with Leon Topalain, president and CEO of steelmaker Nucor . Topalain said Nucor makes products for everything from automotive and agriculture to construction and infrastructure. Topalain said renewable energy, primarily with on- and off-shore wind farms, is a particular fast-growing sector that Nucor is well positioned to capitalize on.

source

Leave a Comment

Your email address will not be published.

Shopping Cart